- Home
- FDBC vs YMAB Comparison
FDBC vs YMAB Comparison
Compare FDBC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDBC
- YMAB
- Stock Information
- Founded
- FDBC 1902
- YMAB 2015
- Country
- FDBC United States
- YMAB United States
- Employees
- FDBC N/A
- YMAB N/A
- Industry
- FDBC Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FDBC Finance
- YMAB Health Care
- Exchange
- FDBC Nasdaq
- YMAB Nasdaq
- Market Cap
- FDBC 253.4M
- YMAB 270.5M
- IPO Year
- FDBC N/A
- YMAB 2018
- Fundamental
- Price
- FDBC $43.45
- YMAB $5.72
- Analyst Decision
- FDBC
- YMAB Strong Buy
- Analyst Count
- FDBC 0
- YMAB 10
- Target Price
- FDBC N/A
- YMAB $21.10
- AVG Volume (30 Days)
- FDBC 5.9K
- YMAB 528.2K
- Earning Date
- FDBC 01-29-2025
- YMAB 03-04-2025
- Dividend Yield
- FDBC 3.68%
- YMAB N/A
- EPS Growth
- FDBC 12.85
- YMAB N/A
- EPS
- FDBC 3.60
- YMAB N/A
- Revenue
- FDBC $79,413,000.00
- YMAB $84,553,000.00
- Revenue This Year
- FDBC N/A
- YMAB $6.41
- Revenue Next Year
- FDBC N/A
- YMAB $18.15
- P/E Ratio
- FDBC $12.00
- YMAB N/A
- Revenue Growth
- FDBC 9.77
- YMAB N/A
- 52 Week Low
- FDBC $41.00
- YMAB $5.60
- 52 Week High
- FDBC $61.21
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- FDBC 42.14
- YMAB 35.08
- Support Level
- FDBC $43.21
- YMAB $5.60
- Resistance Level
- FDBC $45.00
- YMAB $6.57
- Average True Range (ATR)
- FDBC 1.38
- YMAB 0.38
- MACD
- FDBC -0.05
- YMAB 0.10
- Stochastic Oscillator
- FDBC 12.97
- YMAB 11.43
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.